family. Quotient the to welcome Ali,
a from and, press support. like seen by our would As team on leadership you entire made you've executive and we've we updating release dedication recognizing of business to start progress yesterday, Quotient's this key our company's leadership with last continued lot three Quotient our over the for delighted that I'm update – Solution, consistent with be the team. the and business members their I The I update, our team have new position. will make Today, the last executive pillars of by begin mix. our MosaiQ by the business to we of Quotient, transformation enabling progress financial Alba will quarter quarter.
executive will meet in serve able committee, be customers. our better place in new morning, who dynamic our will announced press supplementing read bring have members have knowledge we growth and this you success. As and proven as By initiatives industry records to deep we quarter, track our this earlier of four release our and
pillar Solution. MosaiQ our The is first key
molecular and pipeline, of a diagnostics transfusion disease result more evaluation The immunohematology screening blood proud to the donors. screening. which C was disease regulatory than in included multiple We will the performance submitted. has the with submission dossier begin X,XXX random includes been I'm clinical which expanded announce serological trial immunohematology, Europe,
We sites stated, most is commercially of by all We results work microarray we demonstrated can other use commercial The from instruments. has different approval with are our around or required.' received were easy customers Solution team available Additionally, can how greater Can accepted. Europe average training around better antigen followed And achieved. world launch expect MosaiQ continue be I is The across year-end is than specificities, frankly, the feedback I contains quickly of and one? rest early of received travels relevant Time an limited to in to our excellent. to XX.X% where result on the CE proud feedback we performance in my commercially very CE consistent adopter? that XX specificities get and, the were for positive who world. These 'The Marking the Mark
you on second modality, serological disease to microarrays. like update would the I Now, screening MosaiQ the
Firstly, the disease rapidly as assays or microarray, group in antibodies well hepatitis B the as will HIV-X, track, other is antigen on include C, and microarray, needed O advancing immunoassays, screening surface syphilis expanded X, screening. and core SDS serological blood development sensitivities, hepatitis
are assays meeting known. optimization anti-HCV CTS and requirements antigen requirements, Common drive our with also assays, well array, Our surface sensitivity is than as anti-syphilis R&D European multiplex are team The specificity XXX% progressing Specification planned. Technical the greater we very and continues serving of XX.X as and anti-HIV to where commonly
and so integrate, field a our in refined into ahead the our the modality, the third can market. and accelerate key launch This we launch evaluation, will schedule quarter, plasma in disease plasma MosaiQ submit commercial into Relative in to performance We're previously, molecular strategy to our clinical indicated market. customers fractionation then screening. with of infectious we site as go-to-market this plasma discussions
MosaiQ continue commercial partners. on instrument been execution. with development Shifting our and beyond and has progress make in focus our to We also internal development, assay external
tenders the next locations five the expected time, last within MosaiQ six tenders mentioned Of or years. XX teams the working tenders two Our commercial in been on and technical approximately progress. tender of at have immunohematology evaluations have qualification we the IH
XX committed MosaiQ previously to progressed year-end. still fiscal have on two and this quarter by more are take the three place track With evaluations,
rest US, have of distribution in XX XXX than outside customer closed which world our network, the identified XX distributors. advanced targets, validated next in the and we to to our to Through distribution months. stage XX access more Regarding Europe strategy of the have be an we qualified are
multiple in received geographies. have various from MOUs commitments various We with distributors
received. presence This virtual at quarter, the in our XXXX well conference was AABB
disease have evaluations on the were an Three COVID-XX of over the microarray antibody two virtual on Quotient scientific showcased cytomegalovirus solutions. a received microarray the in treponema and sponsored, attendees, our to conference, antibodies which we detection XXX MosaiQ at pallidum. and visited virtually, signifying As on corporate human the interest MosaiQ one serological booth
performance the Ginocchio, workflow Additionally, we series studies Dr. Solution are of the on by of circle circle, and established impact workflow initiated within Christine a efficiencies. planned the laboratory MosaiQ the membership to be innovator innovator led to demonstrate
Part flexibility and like market transfusion providing are been our you develop has five commercialize and MosaiQ This is new on of I'd to and segments. participants how exploring and our by clinical power information by diagnostics. Solution in opportunities conclude strategy by MosaiQ leveraged on targeting commercialization we've four value. scientific MosaiQ step We new beyond site the a for members to building critical to and update fiscal year-end.
for diagnostic team such for product clinical step Quotient This diagnostics, to options and specific specialties, represents feasibility quarter, first the solutions X food IgE segments. clinical pleased allergens, we in billion the earnings the autoimmune birch and we're towards advanced, such QX Quotient's transplant biopharma pharma, high time, This Janssen. and diagnostic serum new the our to communicated market multiplex allergens. collaboration the clinical allergy IBD MosaiQ same as market. [indiscernible] to weed in at release, announce in In and providing investigating research opportunity and the the automated, and demonstrated we throughput, press call are key detect environmental as tree between as company At
applications. antibody very to successful pleased positivity effort vaccines the are underlining efforts rapidly, IBD collaborative of MosaiQ's infection. MosaiQ broader and technology inform to due rapid power induced antibodies from have the this to development in natural the underline multiplexing continues that MosaiQ Both with very diagnostics diagnostics differentiate for allergy of applications IBD technology of a and for multiplexing power demonstrated way. progressed broader pharma/biopharma This the We vaccine our ability into
on I'd our portfolio. to you like second expansion We Quotient to includes Now, needs. new our way by the announced address the XX on update pillar, Alba by of products The expansion Quotient. Alba customer product the
growth in sales demonstrated Alba an drive in $X.X OEM the XX.X%. Our board, million second growth including performance across impressive and the of business. exceeded XX.X% We've of to above guidance double-digit the continued quarter
reduced We on the you which amendment update obligations our our The pillar of near-term flows. Quotient's XX of that Quotient's secured postponing senior improved by future our to payments negotiated of like I'd significantly cash financial indenture, Finally, on approximately by the debt, months, position. $XX notes the million. principal successful senior third timing cash amendment is
Ali payout Credit And received to like Financial Suisse to guidance. September the million further Funds. to Supply a Additionally, provide over to $X.X Quotient and August in hand Chain now, related would I
